| HOME >> BIOLOGY >> TECHNOLOGY |
49,429,24225,051,48398,385,33449,509,299Income (loss) from operations
328,330(25,018,189)(34,245,115)19,800,634Gain on deconsolidation of OBI
--23,782,229-Equity in net loss of OBI
(668,852)-(1,154,821)-Interest income and other, net
44,31895,860120,705119,102Consolidated net income (loss)
$
(296,204)$ (24,922,329)$ (11,497,002)$ 19,919,736Net loss attributable to noncontrolling interest
-683,483280,344974,288Net income (loss) attributable to Optimer Pharmaceuticals, Inc.
$
(296,204)$ (24,238,846)$ (11,216,658)$ 20,894,024Net income (loss) per share - basic
$
(0.01)$
(0.52)$
(0.24)$
.47Net income (loss) per share - diluted
$
(0.01)$
(0.52)$
(0.24)$
.46Weighted average number of shares used to compute net income (loss) per share - basic
47,234,37146,479,39546,978,49744,581,010Weighted average number of shares used to compute net income (loss) per share - diluted
47,234,37146,479,39546,978,49745,447,261Comprehensive income (loss)
$
(177,625)$ (23,954,597)$ (10,084,685)$ 21,417,416 Optimer Pharmaceuticals, Inc.Condensed Consolidated Balance SheetsJune 30,December 31,20122011(unaudited)ASSETSCurrent assets:Cash and cash equivalents
$ 99,703,307$ 31,787,512Short-term investments
30,934,77478,791,066Trade accounts receivable, net
5,312,4326,563,645Accounts receivable, other
3,181,32052,289,290Inventory
7,962,1123,947,380Prepaid expenses and other current assets
2,326,1223,781,830Total current assets
149,420,067177,160,723Equity investment in OBI
29,013,792-Property and equipment, net
3,693,6702,590,715Long-term investments
882,000882,000Other assets
1,411,0261,389,734Total assets
$ 184,420,555$ 182,023,172LIABILI
'/>"/>
| SOURCE Optimer Pharmaceuticals, Inc. Copyright©2012 PR Newswire. All rights reserved |